COVID-19: UB Planning and Response • Updated 7/2/2020
CRIA faculty members comprise a dynamic research community at UB who make news with their breakthroughs in studying the causes, consequences and biology of addiction.
While volunteering in New York City, UB addiction medicine physician Tildabeth Doscher sees its effects up close
In UB-led study at Hash Bash, frequent users reported low knowledge of, and substantially overestimated, cannabinoid content and effective dosages.
The association between marijuana use and insufficient sleep is especially strong for male and younger students.
Not quite, says a new study that highlights the discrepancy between cannabis enthusiasts’ beliefs about the medicinal and health uses of marijuana and the empirical evidence.
A UB professor and two alums are co-authors of a study in the New England Journal of Medicine that identified vitamin E acetate as a likely culprit.
UB historian David Herzberg says the government has tried to harness a profit-driven drug industry to serve public health before.
Tracey A. Ignatowski, PhD, assistant professor of pathology and anatomical sciences, has developed a treatment for chronic pain that could have an impact in dealing with the opioid crisis.
David Dietz, PhD, associate professor and chair of pharmacology and toxicology, is senior author on a pair of papers dealing with the study of drug relapse.
UB’s Clinical and Research Institute on Addictions (CRIA) is a long-standing national leader in the study of alcohol and substance abuse. For nearly 50 years, CRIA has conducted groundbreaking research on significant addiction issues, including:
Part of UB’s Downtown Campus, CRIA is a key contributor to UB’s reputation for research excellence and a proud member of the Buffalo Niagara Medical Campus.